Host: Aditya Bardia, MD <br>

  Host: Tiffany Traina, MD, FASCO <br>


  
    <p>When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need! </p>

Host: Aditya Bardia, MD Host: Tiffany Traina, MD, FASCO When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need!

Share Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety

Sign up to save your podcasts

Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety

Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety